
🎧 Listen on Spotify: open.spotify.com/episode/0Wh…

Impact with long-acting injectables. RT is not endorsement

🎧 Listen on Spotify: open.spotify.com/episode/0Wh…


Before an innovative treatment can reach patients, one question is essential: is it safe? In the latest Inside Medincell, Aurélie, Preclinical Safety Leader, explains how preclinical safety helps turn long-acting innovation into new treatment options. 👇 Full episode in comments

𝗨𝗭𝗘𝗗𝗬® 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝘀 𝗶𝘁𝘀 𝘀𝘁𝗿𝗼𝗻𝗴 𝗴𝗿𝗼𝘄𝘁𝗵 𝘁𝗿𝗮𝗷𝗲𝗰𝘁𝗼𝗿𝘆 📈 🔹 Q3 U.S. net sales: $85M, +96% YoY 🔹9M 2026: $225M, already above FY2025 For Medincell: growing royalties and further validation of BEPO® at commercial scale. #UZEDY

Heading to #OkinawaColloids2026 🇯🇵 Pierre Berto, PhD, and Feifei Ng, PhD, will represent Medincell, with Pierre presenting new insights into how polymer-based in situ forming depots can be leveraged to tune drug release using BEPO® technology. #DrugDelivery #LongActingInjectables

Medincell is attending the 13th China Healthcare Summit in Shanghai (Nov 2-4). Meet Emma Guo to discuss partnership opportunities and how our BEPO® technology enables long-acting therapeutic innovations. #ChinaHealthcareSummit #LongActingInjectables #BusinessDevelopment

See you at #PODD2026! Looking to unlock the potential of long-acting injectables? Let's discuss how Medincell's BEPO® technology can support your development strategy. See you there. medincell.com #DrugDelivery #Biopharma

Heading to #PharmSci360? Meet the Medincell team in New Orleans! Christophe Roberge & Adolfo Lopez Noriega look forward to connecting and discussing how Medincell's technology platform supports the development of differentiated therapeutic products. 🔗 medincell.com


🎙️ Live webcast Medincell's leadership team will host a press conference to discuss this historic achievement for the company and what comes next. We look forward to sharing this special moment with you! 🔗 Connection link in comments #WELTRUZA

🔗 Read our Press Release: medincell.com/wp-content/upl…

📢 Breaking news: WELTRUZA™ has received U.S. FDA approval for the treatment of adults living with schizophrenia. As the first and only subcutaneous long-acting olanzapine, WELTRUZA™ represents a significant advancement in schizophrenia care. 🔗 Link to PR in comments

Heading to #Sachs_BEF? Meet Medincell in Basel on Oct 7-8 to discuss strategic partnerships, licensing opportunities, and the potential of our BEPO® technology platform. #DrugDelivery #LAI

Ever wonder what a day in the life of a Process Development Engineer looks like 👀? Step into the day of Laura Manzoli, Process Development Engineer at Medincell. 👉 Check out our open positions: bit.ly/4hIokEG #Pharmacareers

Just recorded with Christophe Douat, the CEO of @MedinCell $MEDCL, in Montpellier 🎙️☀️🇫🇷 great story, both personal and the biotech. Out next week!

Skills get you noticed. Mindset helps you thrive. 🎙️ Cédric Bouaraba shares what makes a great fit at Medincell. 👉 Watch full video: youtu.be/sKOPL3T5d9g #Biotech #Careers